Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631267 | 1.00 | L3MBTL1 (0.40) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10613674 | 0.77 | GAA (0.50) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10613679 | 0.77 | GAA (0.50) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL19676040 | 0.77 | LMNA (0.43) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL5360067 | 0.75 | SLC22A1 (0.39) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5360061 | 0.75 | SLC22A1 (0.39) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL19490484 | 0.74 | LMNA (0.40) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL19676090 | 0.74 | LMNA (0.40) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4024136 | 0.73 | LMNA (0.52) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12593473 | 0.73 | LMNA (0.52) | L3MBTL1LMNAALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| EP-1853596-B1 | NOVEL, LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-1911749-B1 | New long-working Beta-2 agonists and their use as medicine | BOEHRINGER INGELHEIM INT (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| EP-2057152-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | Boehringer Ingelheim International GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| EP-2051714-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | Boehringer Ingelheim International GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-7423036-B2 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| EP-1911749-A1 | New long-working Beta-2 agonists and their use as medicine | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008017637-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017638-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| EP-1711480-B1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | BOUYSSOU THIERRY | 2007-03-22 | — | — | US | disclosed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| US-4558061-A | Bronchospasmolytic 1-(3-methanesulfonamido-4-hydroxyphenyl)-2-[(3-(4-acyl-aminophenyl)-imidazolidin-2-one-1-yl)-alkylamino]-ethanols | BOEHRINGER INGELHEIM KG (DE) | 1985-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | ADRB2, ADRB1, CHRM1 | L3MBTL1 3484/4885LMNA 2885/4885ALDH1A1 1450/4885 |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | L3MBTL1 4256/4885LMNA 1248/4885ALDH1A1 1311/4885 |
| US-20060189607-A1 | Long-acting betamimetics for the treatment of respiratory complaints | ADRA1A, ADRA1D, ADRA2A | L3MBTL1 1656/4885LMNA 178/4885ALDH1A1 840/4885 |
| US-20090324510-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | NDUFA1, NDUFA6, NDUFA3 | L3MBTL1 3259/4885LMNA 1604/4885ALDH1A1 189/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | L3MBTL1 3874/4885LMNA 357/4885ALDH1A1 1413/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | L3MBTL1 3482/4885LMNA 2871/4885ALDH1A1 1461/4885 |
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | ADRB1, ADRA1A, ADRB2 | L3MBTL1 1598/4885LMNA 1126/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.